To Identify An Enzyme Or Isoenzyme Patents (Class 435/7.4)
-
Publication number: 20130177923Abstract: Methods are provided of diagnosing, monitoring or determining the severity of disease or injury by measuring individual molecular forms of neutrophil gelatinase-associated lipocalin (NGAL) in bodily fluids, including the diagnosis and monitoring of acute renal injury leading to acute renal failure in a human or mammalian subject by determining the concentration of the free monomer form of NGAL.Type: ApplicationFiled: February 28, 2013Publication date: July 11, 2013Applicant: BioPorto Diagnostics A/SInventor: BioPorto Diagnostics A/S
-
Publication number: 20130177901Abstract: The present invention relates to the prognosis and risk assessment in pregnant women to develop pregnancy-induced hypertension and/or preeclampsia by the determination of marker levels.Type: ApplicationFiled: June 17, 2011Publication date: July 11, 2013Applicant: CEZANNE S.A.S.Inventors: Bruno Darbouret, Gaiane Demirdjian
-
Publication number: 20130177924Abstract: Biosensors, compositions comprising biosensors, methods of producing biosensors, and methods of using biosensors are disclosed. The biosensors comprise a fluorogen-activating peptide and a blocking peptide. The fluorogen-activating peptide and blocking peptide are covalently linked through a peptide linker. The blocking peptide associates with the fluorogen-activating peptide thereby blocking an active domain of the fluorogen-activating peptide when the linker is in an unmodified state. The peptide linker may contain an amino acid sequence that is specifically recognized as a modification substrate by a cognate enzyme. The fluorogen-activating peptide and the blocking peptide at least partially disassociate when the linker is modified by an enzyme, thereby allowing the fluorogen-activating peptide to bind a cognate fluorogen and modulate a fluorescence signal.Type: ApplicationFiled: March 11, 2013Publication date: July 11, 2013Applicant: CARNEGIE MELLON UNIVERSITYInventor: Camegie Mellon University
-
Publication number: 20130171070Abstract: The invention relates to humanized anti-human Factor D monoclonal antibodies, their nucleic acid and amino acid sequences, the cells and vectors that harbor these antibodies and their use in the preparation of compositions and medicaments for treatment of diseases and disorders associated with excessive or uncontrolled complement activation. These antibodies are useful for diagnostics, prophylaxis and treatment of disease.Type: ApplicationFiled: February 5, 2013Publication date: July 4, 2013Applicant: Genentech, Inc.Inventor: Genentech, Inc.
-
Publication number: 20130171624Abstract: This invention describes a general magnetic binding assay method to detect the presence and quantity of analyte in a sample. The method uses magnetic particles for separating and concentrating analytes of interest from complex samples and use time-resolved up-converting fluorescence detection technique to provide highly sensitive detection without using expensive optical components such as band-pass filters. The method uses pulsed long wavelength light for excitation and time-delayed luminescence detection, resulting in little interferences from sample matrices. Furthermore, the usage of long wavelength excitation light requires simpler sample preparation and clean-up such as removal of red blood cells, which otherwise will significantly interfere with excitation efficiency of the fluorescence probes.Type: ApplicationFiled: December 28, 2012Publication date: July 4, 2013Inventor: Aimin He
-
Publication number: 20130171659Abstract: Provided are methods of diagnosing rheumatoid arthritis in a patient by detecting the presence and/or amount of a biomarker of rheumatoid arthritis in a sample from the patient. The methods and biomarkers may be used to develop an accurate prognosis for a patient having rheumatoid arthritis or suspected of having rheumatoid arthritis, or to accurately diagnose a patient having, or suspected of having rheumatoid arthritis. The methods and biomarkers may be used to identify and/or classify a patient as a candidate for a rheumatoid arthritis therapy.Type: ApplicationFiled: December 27, 2012Publication date: July 4, 2013Applicant: ABBOTT JAPAN CO., LTD.Inventors: Kaori Morota, Ryotaro Chiba, Rika Sekiya
-
Publication number: 20130172205Abstract: The present invention relates to the method of determining the risk of acute kidney injury comprising determining the amount of a marker selected from VCAN, NRP1, CCL2, CCL19, COL3A1, GZMM or any combination thereof in a sample.Type: ApplicationFiled: December 4, 2012Publication date: July 4, 2013Inventors: Rainer Oberbauer, Bernd Mayer, Paul Perco, Alexander Kainz
-
Publication number: 20130171123Abstract: This invention provides methods of isolating ferritin from plant and animal material. The isolated ferritin can be administered to humans or animals in need of iron, and can be used to treat or supplement iron deficiency. The isolated ferritin can be used in industrial applications, such as increasing the iron content in heat-processed food or beverages. The methods of the invention also include quantitation of iron derived from plant or animal ferritin.Type: ApplicationFiled: December 28, 2012Publication date: July 4, 2013Applicant: SLOIRON, LLCInventor: Sloiron, LLC
-
Publication number: 20130171661Abstract: A method for assessing the effect of a test compound on LRRK2 in a cell-based system, the method comprising the steps of a) assessing the effect of exposing the cell-based system comprising LRRK2 to the test compound on the phosphorylation state of Ser910 and/or Ser935 of the LRRK2; and/or b) assessing the effect of exposing the cell-based system comprising LRRK2 to the test compound on the binding of the LRRK2 to a 14-3-3 polypeptide. The method may comprise or further comprise the step of assessing the effect of exposing the cell-based system comprising LRRK2 to the test compound on the subcellular location of LRRK2. The method is considered to be useful in assessing the effect of putative LRRK2 inhibitors in cell based systems, including in vivo systems.Type: ApplicationFiled: January 3, 2013Publication date: July 4, 2013Applicant: MEDICAL RESEARCH COUNCILInventor: MEDICAL RESEARCH COUNCIL
-
Publication number: 20130171660Abstract: The present invention provides a blood marker for renal cancer, more specifically, a blood marker that can be practically used for clinical diagnosis of renal cancer. The present invention also provides a blood marker that can be practically used for follow-up after treatment such as surgery and during treatment such as medication for renal cancer. A blood marker for renal cancer selected from the group consisting of Galectin-1, Galectin-3, and ?-enolase. Galectin-1 and/or Galectin-3 as a blood marker for renal cancer for use in an examination performed before diagnostic imaging. ?-Enolase as a blood marker for renal cancer for use in monitoring during and/or after treatment for renal cancer.Type: ApplicationFiled: December 27, 2012Publication date: July 4, 2013Applicants: SHIMADZU CORPORATION, HYOGO COLLEGE OF MEDICINE, EDUCATIONAL CORPORATION MUKOGAWA GAKUINInventors: SHIMADZU CORPORATION, EDUCATIONAL CORPORATION MUKOGAWA GAKUIN, HYOGO COLLEGE OF MEDICINE
-
Publication number: 20130171125Abstract: The present invention relates to methods of preventing or treating cancer and/or decreasing damage to organs or tissues exposed to hypoxic conditions through the use of agents that modulate the expression or activity of SIRT3.Type: ApplicationFiled: May 11, 2011Publication date: July 4, 2013Applicant: National Institutes of Health (NIH), U.S. Dept. of Health and Human Services (DDS), U.S. GovernmentInventors: Marcia C. Haigis, Lydia Finley
-
Publication number: 20130171623Abstract: This invention describes a general binding assay method to detect the presence and quantity of analyte in a sample. The method uses time-resolved up-converting fluorescence detection technique to provide highly sensitive detection without using expensive optical components such as band-pass optical filters. The method uses pulsed long wavelength light for excitation and time-delayed luminescence detection, resulting in little interferences from sample matrices. Furthermore, the usage of long wavelength excitation light requires simpler sample preparation and processing such as removal of red blood cells, which otherwise will significantly interfere with excitation efficiency of the luminescence probes.Type: ApplicationFiled: December 28, 2012Publication date: July 4, 2013Inventor: Aimin He
-
Publication number: 20130164753Abstract: A method of screening for, diagnosing or detecting the presence of Brachyspira sp. Sask30446 and/or colitis in a subject comprising detecting a Brachyspira sp. Sask30446 polynucleotide or polypeptide in a sample of the subject, wherein detection of the Brachyspira sp. Sask30446 polynucleotide or polypeptide is indicative of the presence Brachyspira sp. Sask30446 and/or that the subject has colitis or has an increased risk of developing colitis.Type: ApplicationFiled: July 18, 2011Publication date: June 27, 2013Inventors: John Clare Samuel Harding, Janet Elizabeth Hill, Manuel Chirino, Joseph Rubin
-
Publication number: 20130165344Abstract: The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using a one or more assays configured to detect a kidney injury marker selected from the group consisting of Cancer antigen CA 15-3, C-C Motif chemokine 18, C-C Motif chemokine 24, Cathepsin D, C-X-C Motif chemokine 13, C-C motif chemokine 8, Interleukin-2 receptor alpha chain, Insulin-like growth factor-binding protein 3, Interleukin-11, Matrix Metalloproteinase-8, Transforming growth factor alpha, IgG1, and IgG2 as diagnostic and prognostic biomarkers in renal injuries.Type: ApplicationFiled: June 23, 2011Publication date: June 27, 2013Applicant: ASTUTE MEDICAL, INC.Inventors: Joseph Anderberg, Jeff Gray, Paul McPherson, Kevin Nakamura, James Patrick Kampf
-
Publication number: 20130157288Abstract: Embodiments of this invention include image-based systems and methods for detection of one or more analytes. A surface has identifiable analyte-specific capture particle(s) immobilised thereto at any point of an assay, to which different analytes attach due to the affinity of analyte-specific capture molecule(s) linked to the surface of the capture particle(s) for the analyte. Analyte-specific detector molecules with conjugated detection moieties are then attached to the analyte, and a computer assisted, image-based detection system captures images of the capture particles with or without attached analytes and detector molecules. By using different subsets of analyte-specific capture molecules, each subset having a characteristic identifiable feature; it is now possible to perform capture particle-based, rapid multiplex assays of biological and non-biological analytes without flow.Type: ApplicationFiled: March 4, 2011Publication date: June 20, 2013Inventors: Stephen Kilfeather, Alberto Taurozzi, Paul Lehmann, Elaine Linglee
-
Publication number: 20130156776Abstract: The invention provides methods for treating or decreasing the likelihood of developing a stress-granule related disorder and/or cancer by administering one or more poly-ADP-ribose polymerase (PARP) inhibitors, one or more PARP activators, one or more poly-ADP-ribose glycosylase (PARG) activators, and/or one or more poly-ADP-ribose glycohydrolase ARH3 activators. The invention also provides corresponding methods of decreasing stress granule formation and/or proliferation in a cell or a population of cells. The invention further provides methods of increasing the number of stress granules and proliferation in a cell or a population of cells by administering one or more PARP activators, one or more PARP inhibitors, one or more PARG inhibitors, and/or one or more ARH3 inhibitors.Type: ApplicationFiled: March 30, 2012Publication date: June 20, 2013Applicant: Massachusetts Institute of TechnologyInventors: Paul Chang, Sejal . Vyas, Anthony Leung, Phillip A. Sharp
-
Publication number: 20130157881Abstract: The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using a one or more assays configured to detect a kidney injury marker selected from the group consisting of Coagulation factor VII, CA19-9, Insulin-like growth factor-binding protein 7, C—X—C motif chemokine 6, and C—C motif chemokine 13 as diagnostic and prognostic biomarkers in renal injuries.Type: ApplicationFiled: February 4, 2011Publication date: June 20, 2013Applicant: ASTUTE MEDICAL, INC.Inventors: Joseph Anderberg, Jeff Gray, Paul McPherson, Kevin Nakamura, James Patrick Kampf
-
Publication number: 20130149701Abstract: The present invention relates to methods, compositions, assays and kits for identifying an antibacterial agent that decreases persister formation or survival, eliminates or reduces bacterial infection or disease and/or increases killing of a bacterial cell.Type: ApplicationFiled: June 17, 2011Publication date: June 13, 2013Inventors: Ying Zhang, Wanliang Shi
-
Publication number: 20130149713Abstract: Methods for the use of keratinocyte chemoattractant (KC)/human growth-regulated oncogene (GRO) (KC/GRO), apolipoprotein A2 (APOA2), angiotensinogen r (AGT), thyroglobulin (TG), disintegrin and metalloproteinase domain-containing protein 17 (ADAM17), anionic trypsin-1 (PRSS1), complement C4 (C4A), zona pellucida sperm-binding protein 1 (ZP1), neuropilin-2 (NRP2), solute carrier family 13 member 2 (SLC13A2), glucagon-like peptide 2 receptor (GLP2R), lipoma high mobility group protein isoform I-C (HMGIC) fusion partner-like protein 4 (LHFPL4), and claudin-3 (CLDN3) as biomarkers for diagnosis and prognosis, and for monitoring the efficacy of treatment, in hemorrhagic shock (HS).Type: ApplicationFiled: May 11, 2011Publication date: June 13, 2013Applicant: THE GENERAL HOSPITAL CORPORATIONInventors: Hasan B. Alam, Yongqing Li
-
Publication number: 20130149714Abstract: An implantable diagnostic device in accordance with the present disclosure includes a probe assembly that can be implemented in a variety of ways. A few example implementations include: a needle inside which is located a bio-sensor chip (the needle being insertable into a human being); a compact package containing the bio-sensor chip (the compact package configured for placement inside a catheter); or a silicon-based bio-sensor package configured for insertion into a vein.Type: ApplicationFiled: December 6, 2012Publication date: June 13, 2013Applicants: SANOFI AVENTIS, CALIFORNIA INSTITUTE OF TECHNOLOGYInventors: CALIFORNIA INSTITUTE OF TECHNOLOGY, Sanofi Aventis
-
Publication number: 20130149711Abstract: The present invention relates to new BARD1 isoforms specific to lung cancer and colorectal cancer, a method for detecting thereof and a method for treating and/or preventing lung cancer and colorectal cancer.Type: ApplicationFiled: August 17, 2011Publication date: June 13, 2013Applicants: HOPITAUX UNIVERSITAIRES DE GENEVE, UNIVERSITE DE GENEVEInventors: Irmgard Irminger-Finger, Yong-Qiang Zhang
-
Patent number: 8460891Abstract: Described herein are monoclonal antibodies and methods useful for determining and quantitating the presence of an aryloxyalkanoate dioxygenase enzyme.Type: GrantFiled: June 2, 2011Date of Patent: June 11, 2013Assignee: Dow Agrosciences LLC.Inventors: Guomin Shan, Gaofeng Lin, Joelene K. Smith Drake, Marcelo Sosa
-
Publication number: 20130142829Abstract: Cloning and characterization of a TgIF2? kinase from Toxoplasma gondii designated TgIF2K-D illustrates that this protein is related to GCN2, an eIF2? kinase known to respond to nutrient starvation in other organisms. TgIF2K-D is present in the cytosol of both intra- and extracellular Toxoplasma and facilitates translational control through TgIF2? phosphorylation in extracellular parasites. Both a TgIF2K-D knockout parasite and a parasite harboring the TgIF2? mutant (S71A substitution) exhibited loss of eIF2? kinase activity which manifested itself as significant fitness defect. Accordingly, eIF2? phosphorylation and translational control are an important mechanism by which vulnerable extracellular parasites protect themselves which searching for a new host cell. TgIF2K-D is an excellent target for development of compounds and therapies that can be used to treat infections caused by Toxoplasma and other eukaryotic parasites, especially parasites that have high homology or identity to TgIF2K-D.Type: ApplicationFiled: June 6, 2011Publication date: June 6, 2013Applicant: INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATIONInventors: William J. Sullivan, JR., Ronald C. Wek
-
Publication number: 20130142774Abstract: Provided are compositions comprising newly identified protein fragments of aminoacyl-tRNA synthetases, polynucleotides that encode them and complements thereof, related agents, and methods of use thereof in diagnostic, drug discovery, research, and therapeutic applications.Type: ApplicationFiled: May 2, 2011Publication date: June 6, 2013Applicants: ATYR PHARMA, INC.Inventors: Leslie Ann Greene, Kyle P. Chiang, Fei Hong, Alain Philippe Vasserot, Wing-Sze Lo, Jeffry Dean Watkins, Cheryl L. Quinn, John D. Mendlein
-
Publication number: 20130143236Abstract: The present invention provides a method for determining sensitivity of tumor cells to dasatinib by evaluating inhibitory capacity of a predetermined tyrosine kinase inhibitor in a measurement sample which is prepared from a biological sample containing tumor cells and a computer program.Type: ApplicationFiled: November 29, 2012Publication date: June 6, 2013Inventors: Masaaki KAWAI, Yasuhiro TORIKOSHI, Keigo GOHDA, Hideki ISHIHARA
-
Publication number: 20130143232Abstract: Disclosed herein are methods of detecting and/or prognosing myocardial infarction by detecting a proteolytic fragment of caspase-3 such as the p17 fragment or the p12 fragment. The myocardial infarction can be STEMI or NSTEMI.Type: ApplicationFiled: May 12, 2011Publication date: June 6, 2013Applicants: MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH, UNIVERSITY OF CONNECTICUTInventors: Bruce T. Liang, Heiko Schmitt, Michael Azrin, Christopher C. Pickett, Allan S. Jaffe
-
Patent number: 8455185Abstract: A diagnostic test kit for detecting the presence or quantity of an enzyme or enzyme inhibitor is provided. The diagnostic kit utilizes reactive complexes to facilitate the detection of the enzyme or enzyme inhibitor. The reactive complexes include a substrate joined (e.g., covalently bonded, physically adsorbed, etc.) to a reporter and specific binding member. In one embodiment, for example, a peptide, protein, or glycoprotein substrate is joined to a reporter (e.g., dyed latex particle) and specific binding member (e.g., biotinylated compound). In this embodiment, the substrate provides a cleavage target for a proteolytic enzyme. Specifically, upon contacting the reactive complexes, the proteolytic enzyme cleaves the substrate and releases the reporter and/or specific binding member. The signal exhibited by the released reporters may then be used to indicate the presence or quantity of an enzyme or enzyme inhibitor within the test sample.Type: GrantFiled: February 3, 2011Date of Patent: June 4, 2013Assignee: Kimberly-Clark Worldwide, Inc.Inventor: Xuedong Song
-
Patent number: 8455208Abstract: The present invention provides protein biomarkers for determining whether a thyroid nodule is malignant or benign and methods for using the same.Type: GrantFiled: April 14, 2008Date of Patent: June 4, 2013Assignee: The Regents of the University of ColoradoInventors: Stephen W. Hunsucker, Bryan R. Haugen, Mark W. Duncan, Romana Teodora Maier
-
Publication number: 20130137082Abstract: Provided are a biosensor, an apparatus and a method for detecting a biomolecule using the biosensor. The biosensor may include a supporting substrate, a semiconductor layer spaced apart from a top surface of the supporting substrate by supporting patterns, and a nano-motor array formed on a top surface of the semiconductor layer. The nano-motor array may include a plurality of nano-metal rods configured to exhibit an autonomous propulsion in a fluid.Type: ApplicationFiled: July 10, 2012Publication date: May 30, 2013Applicant: Electronics and Telecommunications Research InstituteInventors: Chan Woo PARK, Jong-Heon YANG, Chil Seong AH, Wan Joong KIM, Kwang Hyo CHUNG, Yo Han CHOI, Gun Yong SUNG
-
Publication number: 20130137595Abstract: A biomarker, method, test kit, and diagnostic system for detecting the presence of lymphoma in a person are disclosed. The lymphoma may be Hodgkin's lymphoma or non-Hodgkin's lymphoma. The person may be a high-risk subject. In one embodiment, a plasma sample from a person is obtained. The level of at least one protein listed in Table S3 in the plasma sample is measured. The level of at least one protein in the plasma sample is compared with the level in a normal or healthy subject. The lymphoma is diagnosed based upon the level of the at least one protein in the plasma sample in comparison to the normal or healthy level.Type: ApplicationFiled: November 30, 2012Publication date: May 30, 2013Applicant: BATTELLE MEMORIAL INSTITUTEInventor: BATTELLE MEMORIAL INSTITUTE
-
Publication number: 20130137116Abstract: A method and kit for detecting the early onset of renal tubular cell injury, utilizing NGAL as an early urinary biomarker. NGAL is a small secreted polypeptide that is protease resistant and consequently readily detected in the urine following renal tubule cell injury. NGAL protein expression is detected predominantly in proximal tubule cells, in a punctate cytoplasmic distribution reminiscent of a secreted protein. The appearance of NGAL in the urine is related to the dose and duration of renal ischemia and nephrotoxemia, and is diagnostic of renal tubule cell injury and renal failure. NGAL detection is also a useful marker for monitoring the nephrotoxic side effects of drugs or other therapeutic agents.Type: ApplicationFiled: February 6, 2013Publication date: May 30, 2013Inventors: Prasad DEVARAJAN, Jonathan M. Barasch
-
Publication number: 20130130275Abstract: Methods and kits for reducing non-specific binding in an immunoassay for PIVKA-II in a test sample are described, in which the test sample is reacted with an anti-prothrombin antibody in the presence of one or more of the following additives: skim milk, saponin, CaCl2, MgCl2, and a sulfobetaine zwitterionic detergent.Type: ApplicationFiled: May 16, 2012Publication date: May 23, 2013Applicant: ABBOTT JAPAN CO., LTD.Inventors: Toru Yoshimura, Eisaku Yoshida, Ryotaro Chiba
-
Publication number: 20130130931Abstract: The present invention provides a new biomarker for the diagnosis, prognosis and monitoring of cancer, preferably breast and colon cancer, the PIK3R2 gene or any of its expression products; since high levels of PIK3R2 correlate with advanced tumor stages, and in the case of breast cancer, with invasive or metastatic capacity. Thus, the invention is also related to a method for the diagnosis, prognosis and monitoring of cancer, preferably breast or colon cancer, in which the quantification of said biomarker in a biological sample comprising tumor cells is necessary.Type: ApplicationFiled: January 22, 2013Publication date: May 23, 2013Applicant: CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC)Inventor: CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC)
-
Publication number: 20130129704Abstract: Provided are compositions comprising newly identified protein fragments of aminoacyl-tRNA synthetases, polynucleotides that encode them and complements thereof, related agents, and methods of use thereof in diagnostic, drug discovery, research, and therapeutic applications.Type: ApplicationFiled: April 27, 2011Publication date: May 23, 2013Applicants: PANGU BIOPHARMA LIMITED, ATYR PHARMA, INC.Inventors: Leslie Ann Greene, Kyle P. Chiang, Fei Hong, Alain Philippe Vasserot, Wing-Sze Lo, Jeffry Dean Watkins, Cheryl L. Quinn, John D. Mendlein
-
Publication number: 20130131153Abstract: Cullin5 (Cul5) E3 ubiquitin ligase is shown to be linked with the heat shock protein 90 (Hsp90) chaperone complex. Hsp90 participates in the folding of its client proteins into their functional conformation. Many Hsp90 clients have been reported to be aberrantly expressed in a number of cancers. Cul5 is shown to interact with members of the Hsp90 chaperone complex as well as the Hsp90 client, ErbB2, Cul5 is recruited to the site of ErbB2 at the plasma membrane and subsequent induction of polyubiquitination and proteasomal degradation. Cul5 is also involved in the regulation of another Hsp90 client, Hif-1? Cul5 degradation of ErbB2 occurs independently of ElonginB-ElonginC function. The involvement of Cul5 in Hsp90 client regulation has implications in the effectiveness of Hsp90 targeted chemotherapy, which is currently undergoing clinical trials. The link between Cul5 and Hsp90 client regulation may represent an avenue for cancer drug development.Type: ApplicationFiled: November 16, 2010Publication date: May 23, 2013Applicant: THE JOHNS HOPKINS UNIVERSITYInventors: Xiao-Fang Yu, Elana S. Ehrlich, Rongzhen Xu
-
Publication number: 20130130281Abstract: Accurate and fast detection of the presence of Clostridium difficile (C. difficile) disease is crucial for the proper treatment of patients with C. difficile infection. Present tests detecting the presence of C. difficile disease are fast and cost effective, but are not very sensitive. Using an ELISA including Cell Wall Protein 84 (Cwp84) increases the sensitivity of the ELISA. Cwp84 may be used alone or in combination with other markers to support a diagnosis of C. difficile-associated disease.Type: ApplicationFiled: September 25, 2012Publication date: May 23, 2013Applicant: TECHLAB, INC.Inventor: TECHLAB, INC.
-
Publication number: 20130129673Abstract: Oligodendrocytes (OLs), the predominant cell type found in cerebral white matter, are essential for structural integrity and proper neural signaling. Very little is known concerning stroke-induced OL dysfunction. Infusion of human umbilical cord blood (HUCB) cells protects striatal white matter tracts in vivo and directly protects mature primary OL cultures from oxygen glucose deprivation (OGD). Microarray studies of RNA prepared from OL cultures subjected to OGD and treated with HUCB cells showed an increase in the expression of 33 genes associated with OL proliferation, survival, and repair functions, such as myelination. Immunohistochemistry showed antioxidant protein expression was upregluated in the ipsilateral white matter tracts of rats infused with HUCB cells 48 hrs after middle cerebral artery occlusion (MCAO). These results show expression of genes induced by HUCB cell therapy that could confer oligoprotection from ischemia.Type: ApplicationFiled: August 27, 2012Publication date: May 23, 2013Applicant: UNIVERSITY OF SOUTH FLORIDAInventors: Keith Ronald Pennypacker, Alison Elizabeth Willing
-
Publication number: 20130130276Abstract: The object of the present invention is to provide a method for detecting gastric cancer, and a kit for detecting gastric cancer. The object can be solved by a method for detecting gastric cancer characterized by analyzing ?1,4-N-acetylgalactosamine transferase 1. According to the present invention, gastric cancer patients can be detected at high rates, even early stage gastric cancer patients without a subjective symptom.Type: ApplicationFiled: May 17, 2011Publication date: May 23, 2013Applicants: School Juridical Person Kitasato Institute, Tokyo Institute of TechnologyInventors: Katsuko Yamashita, Keiko Fukushima, Masahiko Watanabe, Keishi Yamashita
-
Publication number: 20130131144Abstract: The present invention relates to compositions to treat glycerophosphodiester phosphodiesterase (GDE) related disorders. The invention also relates to methods treating GDE related disorders. The invention further relates to kits for treating GDE related disorders in a subject. The invention further relates to methods of identifying novel treatments for treating GDE related disorders in a subject.Type: ApplicationFiled: October 26, 2012Publication date: May 23, 2013Applicant: THE JOHNS HOPKINS UNIVERSITYInventor: The Johns Hopkins University
-
Publication number: 20130131139Abstract: Disclosed are methods of selecting a subject suspected of having or having leukemia, such as lymphoblast leukemia (B-ALL), for treatment with an agent that inhibits ROR1-regulated signaling activity. In some examples, cells obtained from the subject are screened for over expression of ROR1. In other examples, the cells are contacted with an agent that inhibits ROR1 signaling activity and a ROR1-regulated signaling activity is detected. An alteration in the ROR1-regulated signaling activity as compared to a control identifies the subject as one that would benefit from treatment with an agent that inhibits ROR1 signaling activity. Also disclosed are methods for identifying an agent for treating a subject with a ROR1-dependent leukemia or with a predisposition for developing a ROR1-dependent leukemia, and methods for treating or inhibiting a ROR1-dependent leukemia, such as B-ALL in a subject.Type: ApplicationFiled: November 17, 2011Publication date: May 23, 2013Inventors: Jeffrey W. Tyner, Brian J. Druker, Vincent Bicocca, Bill H. Chang
-
Publication number: 20130130277Abstract: A method of screening a compound having a hypoglycemic effect (hereinafter referred to as “hypoglycemic compound”), a remedy for diabetes which contains a compound having a novel function mechanism, etc. More specifically speaking, a method of screening a hypoglycemic compound capable of binding to the ? subunit of a trimeric GTP-binding protein, a remedy for diabetes comprising a hypoglycemic compound, which is characterized by being capable of binding to the ? subunit of a trimeric GTP-binding protein, as the active ingredient, etc.Type: ApplicationFiled: December 10, 2012Publication date: May 23, 2013Applicant: AJINOMOTO CO., INC.Inventor: AJINOMOTO CO., INC.
-
Publication number: 20130130243Abstract: The present invention relates to a method for detecting and quantifying an analyte present in a liquid of interest using a solid support, the surface of which comprises at least one active area on which at least one probe capable of binding said analyte is immobilized and a solution containing at least one secondary reagent capable of binding to the analyte, said method comprising a step consisting of recycling said solution in order to put it back into contact with the surface and notably with the active area at least one additional time. The present invention also relates to a device which may be applied within the scope of such a method.Type: ApplicationFiled: April 22, 2011Publication date: May 23, 2013Applicant: Commissariat a L'Energie Atomique ET Aux Energies AlternativesInventors: Thierry Livache, Roberto Calemczuk, Malika Amdaoud
-
Publication number: 20130129750Abstract: The application discloses PERLECAN as a new biomarker for renal dysfunction; methods for predicting, diagnosing, prognosticating and/or monitoring said dysfunction based on measuring said biomarker; and kits and devices for measuring said biomarker and/or performing said methods.Type: ApplicationFiled: August 5, 2011Publication date: May 23, 2013Applicant: PRONOTA N.V.Inventors: Koen Kas, Griet Vanpoucke, Piet Moerman
-
Patent number: 8444957Abstract: The present invention provide purified Flt4 receptor tyrosine kinase polypeptides and fragments thereof, polynucleotides encoding such polypeptides, antibodies that specifically bind such polypeptides, and uses therefor.Type: GrantFiled: February 17, 2010Date of Patent: May 21, 2013Assignee: Vegenics Pty LimitedInventors: Kari Alitalo, Arja Kaipainen, Rejia Valtola, Lolla Jussila
-
Publication number: 20130122485Abstract: Provided are methods of analyzing biomaterials using a magnetic bead. The method may include preparing a bio material including a target material, preparing first and second magnetic beads, the second magnetic bead having a size smaller than that of the first magnetic bead, forming a binding element including the target material bound on the first and second magnetic beads, separating the first magnetic bead from the binding element by using a magnet, and quantifying the target material bound on the second magnetic bead.Type: ApplicationFiled: November 2, 2012Publication date: May 16, 2013Applicant: Electronics and Telecommunications Research InstituteInventor: Electronics and Telecommunications Reseach Ins
-
Publication number: 20130123328Abstract: We describe a method of determining whether a cancer cell is likely to be resistant to treatment by an mTOR inhibitor. The method may comprise detecting PPP2R2B (GenBank Accession Number: NM_18167) in or of the cell. It may, alter-natively, or in addition, comprise detecting PDK1 (GenBank Accession Number: NM_002613), in or of the cell. The method may comprise detecting methylation of the PPP2R2B promoter in or of the cell. It may comprise detecting the expression and/or activity of PPP2R2B in or of the cell. It may comprise detecting PDK1 mediated Myc phosphorylation activity.Type: ApplicationFiled: January 10, 2011Publication date: May 16, 2013Applicant: AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCHInventors: Qiang Yu, Jing Tan
-
Publication number: 20130122518Abstract: A panel for monitoring levels of biomarkers, including an assay having at least one inflammation monitoring test, at least one oxidative stress monitoring test, and at least one antioxidant activity monitoring test. A method of monitoring an individual's health, by collecting a sample from the individual, applying the sample to an assay panel, performing at least one inflammation monitoring test, at least one oxidative stress monitoring test, and at least one antioxidant activity monitoring test in the panel, and determining levels of biomarkers related to inflammation, oxidative stress, and antioxidant activity and therefore providing information regarding the individual's relative health and/or risk of developing one or more diseases.Type: ApplicationFiled: July 21, 2011Publication date: May 16, 2013Applicant: WELLNESS INDICATORS, INC.Inventors: Denis M. Callewaert, Andrew A. Dahl
-
Patent number: 8440417Abstract: An exemplary embodiment may be directed to a fluorescence polarization assay that screens compounds or agents for their affinity to hematopoietic prostaglandin D synthase (H-PGDS) based on their ability to displace a fluorophore-containing detection analyte bound to an enzyme comprising the primary amino acid sequence of H-PGDS. Another exemplary embodiment utilizes an enzyme having a maltose binding protein amino-acid sequence fused with an N-terminus of the enzyme.Type: GrantFiled: May 13, 2009Date of Patent: May 14, 2013Assignee: Cayman Chemical Company, IncorporatedInventors: Nisha Palackal, Jeffrey K. Johnson, Karie L. McGowan, Kirk W. Maxey, Gregory W. Endres
-
Publication number: 20130116343Abstract: A method of diagnosing a patient's risk of breast cancer comprises measuring in a saliva sample from the patient a concentration of at least a first protein marker, wherein the first protein marker is either ubiquitin or cytochrome p450, to provide a set of test data comprising a concentration value of each protein marker in the saliva sample. The test values are then compared to a reference panel comprising a Reference Control Value and a Reference Breast Cancer Value, and a diagnosis of either increased or decreased risk of breast cancer is determined for the patient based on a result of that comparison. A test kit for identifying a person at increased risk of breast cancer is also provided.Type: ApplicationFiled: April 21, 2011Publication date: May 9, 2013Applicant: BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEMInventors: Charles F. Streckfus, William P. Dubinsky, Lenora Bigler, Karen A. Storthz, Daniel Arreola
-
Publication number: 20130116280Abstract: A fusion protein including N-terminal domain of a fusion partner at N-terminal and C-terminal domain of RET protein at C-terminal, a fusion gene encoding the fusion protein, and a use of the fusion protein or the fusion gene as a diagnosing marker for a cancer, are provided.Type: ApplicationFiled: October 30, 2012Publication date: May 9, 2013Applicant: Macrogen Inc.Inventor: Macrogen Inc.